GlassScriptPhysician profile
Erik Stuart Diebolt
NPI 1386901072
$2,181.82
in general payments reported to CMS, 2019-2025
14 companies · $395 in 2025
The $395 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $978 · 2021: $220 · 2022: $154 · 2023: $56.92 · 2024: $180 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372 · Travel and Lodging: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.86 |
| Travel and Lodging | $260.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,437.52 | 2019-2024 | |
| Stryker Corporation | $355.65 | 2025 | Mild Device Kit, Optablate |
| Nevro Corp. | $76.83 | 2019-2024 | Senza |
| Medtronic, INC. | $65.73 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $42.75 | 2023-2024 | Proclaim |
| Ucb, INC. | $31.24 | 2024 | Rystiggo |
| Teva Pharmaceuticals USA, INC. | $25.13 | 2021 | |
| Horizon Therapeutics Plc | $24.60 | 2020 | |
| Abbvie INC. | $24.18 | 2025 | |
| Genentech USA, INC. | $23.87 | 2024 | Ocrevus |
| Upsher-Smith Laboratories LLC | $21.24 | 2021 | |
| Adamas Pharmaceuticals, INC. | $20.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.79 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Diebolt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.